13G Filing: Nantahala Capital Management and Aeglea Bio Therapeutics Inc (AGLE)

Page 1 of 7

Aeglea Bio Therapeutics Inc (NASDAQ:AGLE): Wilmot B. Harkey And Daniel Mack’s Nantahala Capital Management filed an amended 13D.

You can check out Nantahala Capital Management’s latest holdings and filings here.

Please follow Nantahala Capital Management (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Nantahala Capital Management or update its stock holdings.

Wilmot B. Harkey And Daniel Mack
Wilmot B. Harkey And Daniel Mack
Nantahala Capital Management

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Nantahala Capital Management 0 1,813,573 0 1,813,573 1,813,573 10.9%
Wilmot B. Harkey 0 1,813,573 0 1,813,573 1,813,573 10.9%
Daniel Mack 0 1,813,573 0 1,813,573 1,813,573 10.9%
Wilmot B. Harkey And Daniel Mack
Wilmot B. Harkey And Daniel Mack
Nantahala Capital Management

Page 1 of 7 – SEC Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

Under the Securities Exchange Act of
1934

(Amendment No.)*

AEGLEA
BIOTHERAPEUTICS, INC.

(Name of Issuer)

Common Stock, $.0001 par value

(Title of Class of Securities)

00773J103

(CUSIP Number)

November 30, 2017

(Date of Event which Requires Filing of
this Statement)

Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:

x  Rule 13d-1(b)
¨  Rule 13d-1(c)
¨  Rule 13d-1(d)

*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any
subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).

Continued on following pages

Page 1 of 7 Pages

Follow Aeglea Biotherapeutics Inc. (NASDAQ:AGLE)
Page 1 of 7